Ticagrelor + Clopidogrel + Aspirin
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Stable Coronary Artery Disease
Conditions
Stable Coronary Artery Disease
Trial Timeline
May 1, 2008 → Mar 1, 2009
NCT ID
NCT00642811About Ticagrelor + Clopidogrel + Aspirin
Ticagrelor + Clopidogrel + Aspirin is a phase 2 stage product being developed by AstraZeneca for Stable Coronary Artery Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00642811. Target conditions include Stable Coronary Artery Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00642811 | Phase 2 | Completed |
Competing Products
20 competing products in Stable Coronary Artery Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| eFT508 + Avelumab | eFFECTOR Therapeutics | Phase 2 | 44 |
| Atorvastatin 20mg loading + Atorvastatin 80mg loading | Yuhan | Approved | 85 |
| ASP7991 | Astellas Pharma | Phase 1 | 33 |
| Epoetin Alfa + Roxadustat | Astellas Pharma | Phase 3 | 77 |
| TRC041266 + Placebo | Torrent Pharmaceuticals | Phase 3 | 77 |
| Evorpacept (ALX148) + Cetuximab + Pembrolizumab | Eli Lilly | Phase 2 | 52 |
| budesonide/formoterol + formoterol | AstraZeneca | Phase 2 | 52 |
| Inhibition of Platelet Aggregation by "Brilinta"(Ticagrelor) | AstraZeneca | Approved | 85 |
| TC-5214 + Placebo | AstraZeneca | Phase 1 | 33 |
| ticagrelor + clopidogrel | AstraZeneca | Phase 2 | 52 |
| Ticagrelor + Clopidogrel | AstraZeneca | Approved | 85 |
| Ticagrelor + Clopidogrel | AstraZeneca | Approved | 85 |
| grapiprant + grapiprant and pembrolizumab | Merck | Phase 1 | 33 |
| Bevacizumab + Capecitabine + Pembrolizumab | Merck | Phase 2 | 52 |
| Nicorandil + Standard Treatment | Merck | Approved | 85 |
| BPS804 + Placebo | Novartis | Phase 2 | 52 |
| CLR325 | Novartis | Phase 2 | 52 |
| Erenumab + Placebo | Amgen | Phase 2 | 51 |
| Ranolazine + Placebo | Gilead Sciences | Approved | 84 |
| ranolazine + placebo | Gilead Sciences | Approved | 84 |